Journal of the Korean Ophthalmological Society 1996;37(10):1595-1600.
Published online October 1, 1996.
Inhibition of Basic Fibroblast Growth Factor Induced Corneal Angiogenesis by a Urokinase Plasminogen Activator Receptor Antagonist.
Sung Kun Chung, Ja Young Lee, David G Hwang
1Department of Ophthalmology, Catholic University, Medical College, Seoul, Korea.
2Department of Ophthalmology, University of California San Francisco, San Francisco, CA, U.S.A.
각막 혈관생성에 있어서 urokinase plasminogen activator 수용체에 대한 길항체의 억제효과
정성근(Sung Kun Chung) , 이자영(Ja Young Lee) , (David G . Hwang)
Abstract
During angiogenesis, expression of urokinase plasminogen activator(uPA) and its receptor(uPAR) is upregulated in vascular endothelial cells. Binding of uPA to uPAR has been implicated as an important component of the angiogenesis pathway and represents a potential target for the design of anti-angiogenic compounds. We have produced a high-affinity competitive antagonist for the uPA receptor consisting of a fusion protein linking the endothelial growth factor (EGF)-like domain of uPA (residues 1-48) to the Fc domain of IgG. To determine whether this recombinant murine uPA(1-48)-IgG fusion protein could interfere with angiogenesis we studied the effect of this compound on rabbit corneal angiogenesis induced by basic fibroblast growth factor(bFGF). A hydrogel disk containing 1000ng of bFGF was implanted intrastromally into the superior cornea of each of sixteen New Zealand white rabbit eyes. All eyes received a second intrastromal disk, randomized to contain either 35 microgram of uPA(1-48)-IgG fusion protein(n=8) or phosphate-buffered saline(PBS)(n=8). Both disks were positioned side-by-side, 1.2 mm from the superior limbus. At three days post-implantation of bFGF disks, eyes treated with uPA(1-48)-IgG fusion protein had reduced angiogenesis(mean score=2.2) compared to PBS-treated controls (mean score=5.1)(p<0.05, Wilcoxon rank sum test). In a rabbit corneal pocket assay, murine uPA(1-48)-IgG fusion protein appears to inhibit bFGF-induced angiogenesis. Compounds that block uPAR binding of uPA may have therapeutic potential as anti-angiogenic agents.
Key Words: Angiogenesis;Corneal pocket assay;Urokinase plasminogen activator receptor antagonist


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next